The histone H3K79 methyltransferase DOT1L (KMT4; Dot1 in yeast) is an epigenetic enzyme for which inhibitors are in clinical development for the treatment of MLL‐rearranged (MLL‐r) leukemia (Stein & Tallman, 2016). This evidence concerns the gene KMT2A and leukemia.